Does the media refer more to JANX or MGNX?

In the previous week, Janux Therapeutics had 5 more articles in the media than MacroGenics. MarketBeat recorded 8 mentions for Janux Therapeutics and 3 mentions for MacroGenics. Janux Therapeutics' average media sentiment score of 0.96 beat MacroGenics' score of 0.57 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MGNX or ANNX?

MacroGenics has higher revenue and earnings than Annexon. MacroGenics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $175.14M 1.51 -$74.62M -$0.22 N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is MGNX or ANNX more profitable?

Annexon has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Annexon's return on equity of -106.15% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% Annexon N/A -106.15% -79.82%

Does the media refer more to MGNX or ANNX?

In the previous week, MacroGenics and MacroGenics both had 3 articles in the media. Annexon's average media sentiment score of 1.05 beat MacroGenics' score of 0.57 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MGNX or CLYM more profitable?

Climb Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Climb Bio's return on equity of -31.79% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% Climb Bio N/A -31.79% -30.79%

Does the media refer more to MGNX or CLYM?

In the previous week, Climb Bio had 6 more articles in the media than MacroGenics. MarketBeat recorded 9 mentions for Climb Bio and 3 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.57 beat Climb Bio's score of 0.41 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, MGNX or GERN?

MacroGenics has higher earnings, but lower revenue than Geron. MacroGenics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $175.14M 1.51 -$74.62M -$0.22 N/A Geron $204.56M 4.82 -$83.50M -$0.11 N/A

Is MGNX or GERN more profitable?

MacroGenics has a net margin of -8.70% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -8.70% -109.26% -18.70% Geron -34.17% -24.48% -10.30%

Does the media refer more to MGNX or GERN?

In the previous week, MacroGenics had 1 more articles in the media than Geron. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Geron. MacroGenics' average media sentiment score of 0.57 beat Geron's score of 0.51 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLDB or MGNX?

In the previous week, Solid Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Solid Biosciences and 3 mentions for MacroGenics. Solid Biosciences' average media sentiment score of 0.82 beat MacroGenics' score of 0.57 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MacroGenics (MGNX) Competitors

$4.15 +0.13 (+3.23%)

As of 03:00 PM Eastern

Compare

MGNX vs. JANX, ANNX, CLYM, GERN, and SLDB

Should you buy MacroGenics stock or one of its competitors? MacroGenics's main competitors and comparable companies include Janux Therapeutics (JANX), Annexon (ANNX), Climb Bio (CLYM), Geron (GERN), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MacroGenics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Janux Therapeutics' return on equity of -11.89% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
MacroGenics	-8.70%	-109.26%	-18.70%

Janux Therapeutics currently has a consensus price target of $36.46, indicating a potential upside of 93.84%. MacroGenics has a consensus price target of $6.33, indicating a potential upside of 52.43%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Janux Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Janux Therapeutics had 5 more articles in the media than MacroGenics. MarketBeat recorded 8 mentions for Janux Therapeutics and 3 mentions for MacroGenics. Janux Therapeutics' average media sentiment score of 0.96 beat MacroGenics' score of 0.57 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

MacroGenics has higher revenue and earnings than Janux Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24M	47.92	-$113.62M	-$1.64	N/A
MacroGenics	$175.14M	1.51	-$74.62M	-$0.22	N/A

Summary

Janux Therapeutics beats MacroGenics on 12 of the 17 factors compared between the two stocks.

How does MacroGenics compare to Annexon?

MacroGenics (NASDAQ:MGNX) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

MacroGenics has higher revenue and earnings than Annexon. MacroGenics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.51	-$74.62M	-$0.22	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 10.3% of Annexon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MacroGenics currently has a consensus target price of $6.33, suggesting a potential upside of 52.43%. Annexon has a consensus target price of $15.33, suggesting a potential upside of 197.45%. Given Annexon's stronger consensus rating and higher possible upside, analysts plainly believe Annexon is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Annexon has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Annexon's return on equity of -106.15% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Annexon	N/A	-106.15%	-79.82%

In the previous week, MacroGenics and MacroGenics both had 3 articles in the media. Annexon's average media sentiment score of 1.05 beat MacroGenics' score of 0.57 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MacroGenics and Annexon tied by winning 7 of the 14 factors compared between the two stocks.

How does MacroGenics compare to Climb Bio?

MacroGenics (NASDAQ:MGNX) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Climb Bio has lower revenue, but higher earnings than MacroGenics. Climb Bio is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.51	-$74.62M	-$0.22	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

In the previous week, Climb Bio had 6 more articles in the media than MacroGenics. MarketBeat recorded 9 mentions for Climb Bio and 3 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.57 beat Climb Bio's score of 0.41 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Climb Bio's return on equity of -31.79% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Climb Bio	N/A	-31.79%	-30.79%

MacroGenics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

MacroGenics presently has a consensus target price of $6.33, suggesting a potential upside of 52.43%. Climb Bio has a consensus target price of $23.08, suggesting a potential upside of 28.89%. Given MacroGenics' higher probable upside, equities research analysts clearly believe MacroGenics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

MacroGenics beats Climb Bio on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Geron?

MacroGenics (NASDAQ:MGNX) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

MacroGenics has a net margin of -8.70% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Geron	-34.17%	-24.48%	-10.30%

MacroGenics has higher earnings, but lower revenue than Geron. MacroGenics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$175.14M	1.51	-$74.62M	-$0.22	N/A
Geron	$204.56M	4.82	-$83.50M	-$0.11	N/A

MacroGenics currently has a consensus target price of $6.33, indicating a potential upside of 52.43%. Geron has a consensus target price of $4.00, indicating a potential upside of 160.59%. Given Geron's stronger consensus rating and higher possible upside, analysts clearly believe Geron is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MacroGenics had 1 more articles in the media than Geron. MarketBeat recorded 3 mentions for MacroGenics and 2 mentions for Geron. MacroGenics' average media sentiment score of 0.57 beat Geron's score of 0.51 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Geron beats MacroGenics on 8 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Solid Biosciences currently has a consensus target price of $17.40, indicating a potential upside of 77.73%. MacroGenics has a consensus target price of $6.33, indicating a potential upside of 52.43%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Solid Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

MacroGenics has higher revenue and earnings than Solid Biosciences. MacroGenics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
MacroGenics	$175.14M	1.51	-$74.62M	-$0.22	N/A

In the previous week, Solid Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Solid Biosciences and 3 mentions for MacroGenics. Solid Biosciences' average media sentiment score of 0.82 beat MacroGenics' score of 0.57 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Solid Biosciences' return on equity of -71.35% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
MacroGenics	-8.70%	-109.26%	-18.70%

Solid Biosciences has a beta of 2.41, meaning that its share price is 141% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Summary

Solid Biosciences beats MacroGenics on 9 of the 15 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$264.67M	$4.04B	$7.33B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-18.89	11.73	271.22	24.16
Price / Sales	1.51	1,431.77	696.48	128.34
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	4.72	17.51	11.33	6.51
Net Income	-$74.62M	-$22.72M	$3.46B	$347.63M
7 Day Performance	1.59%	4.59%	2.92%	1.50%
1 Month Performance	12.30%	12.04%	8.55%	5.15%
1 Year Performance	153.35%	60.45%	27.54%	17.73%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.5889 of 5 stars	$4.15 +3.2%	$6.33 +52.6%	+137.9%	$265.31M	$175.14M	N/A	430
JANX Janux Therapeutics	3.7372 of 5 stars	$16.96 +4.3%	$37.58 +121.6%	-23.5%	$1.04B	$10M	N/A	30	Analyst Upgrade
ANNX Annexon	3.0094 of 5 stars	$5.28 +2.9%	$15.33 +190.4%	+119.0%	$1.00B	N/A	N/A	60	Positive News
CLYM Climb Bio	2.5184 of 5 stars	$17.39 -0.3%	$22.75 +30.8%	+589.1%	$998.81M	N/A	N/A	9	Analyst Forecast Gap Up
GERN Geron	1.933 of 5 stars	$1.53 flat	$4.00 +161.4%	+4.1%	$982.98M	$183.88M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. JANX, ANNX, CLYM, GERN, and SLDB

How does MacroGenics compare to Janux Therapeutics?

Summary

How does MacroGenics compare to Annexon?

Summary

How does MacroGenics compare to Climb Bio?

Summary

How does MacroGenics compare to Geron?

Summary

How does MacroGenics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. JANX, ANNX, CLYM, GERN, and SLDB

How does MacroGenics compare to Janux Therapeutics?

Do insiders and institutionals believe in JANX or MGNX?

Is JANX or MGNX more profitable?

Do analysts rate JANX or MGNX?

Does the media refer more to JANX or MGNX?

Which has more volatility & risk, JANX or MGNX?

Which has preferable valuation and earnings, JANX or MGNX?

Summary

How does MacroGenics compare to Annexon?

Which has more volatility & risk, MGNX or ANNX?

Which has better earnings and valuation, MGNX or ANNX?

Do institutionals and insiders hold more shares of MGNX or ANNX?

Do analysts prefer MGNX or ANNX?

Is MGNX or ANNX more profitable?

Does the media refer more to MGNX or ANNX?

Summary

How does MacroGenics compare to Climb Bio?

Which has stronger valuation and earnings, MGNX or CLYM?

Does the media refer more to MGNX or CLYM?

Is MGNX or CLYM more profitable?

Which has more risk and volatility, MGNX or CLYM?

Do analysts rate MGNX or CLYM?

Do insiders and institutionals believe in MGNX or CLYM?

Summary

How does MacroGenics compare to Geron?

Which has more volatility and risk, MGNX or GERN?

Is MGNX or GERN more profitable?

Which has better valuation & earnings, MGNX or GERN?

Do analysts prefer MGNX or GERN?

Do institutionals & insiders have more ownership in MGNX or GERN?

Does the media refer more to MGNX or GERN?

Summary

How does MacroGenics compare to Solid Biosciences?

Do insiders and institutionals believe in SLDB or MGNX?

Do analysts rate SLDB or MGNX?

Which has higher earnings & valuation, SLDB or MGNX?

Does the media prefer SLDB or MGNX?

Is SLDB or MGNX more profitable?

Which has more risk and volatility, SLDB or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools